GlassScriptPhysician profile
Stephanie Frank
NPI 1477951895
$12,084.10
in general payments reported to CMS, 2019-2025
45 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,403 · 2022: $1,515 · 2023: $4,073 · 2024: $3,732 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,154 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,154.32 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,644.33 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,210.58 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neuronetics, INC. | $808.35 | 2022-2024 | Neurostar Tms Therapy System |
| Alkermes, INC. | $731.50 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $590.04 | 2021-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $512.23 | 2023-2025 | Spravato, Invega Sustenna, Invega |
| Vanda Pharmaceuticals INC. | $492.63 | 2023-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $481.55 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $447.43 | 2021-2024 | Caplyta |
| Axsome Therapeutics, INC. | $403.24 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $386.86 | 2021-2025 | Qelbree |
| Noven Therapeutics, LLC | $273.81 | 2023-2024 | Xelstrym, Secuado |
| Argenx US, INC. | $230.50 | 2025 | Vyvgart |
| Almatica Pharma LLC | $215.37 | 2023-2024 | Loreev Xr, Teriparatide, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $190.27 | 2021-2024 | Trintellix |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.